Adial Pharmaceuticals マネジメント

マネジメント基準チェック /44

Adial Pharmaceuticalsの CEO はCary Claiborneで、 Aug2022年に任命され、の在任期間は 2.25年です。の年間総報酬は$ 801.62Kで、 58.1%給与と41.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.95%を直接所有しており、その価値は$ 61.41K 。経営陣と取締役会の平均在任期間はそれぞれ3年と7.3年です。

主要情報

Cary Claiborne

最高経営責任者

US$801.6k

報酬総額

CEO給与比率	58.1%
CEO在任期間	2.3yrs
CEOの所有権	0.9%
経営陣の平均在職期間	3yrs
取締役会の平均在任期間	7.3yrs

経営陣の近況

Recent updates

Adial Clinical Trial: A Fluff Or A Win?

Aug 22

Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01

Aug 16

Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst

Jun 21

Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate

Jan 11

Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital

Nov 25

CEO報酬分析

Adial Pharmaceuticals の収益と比較して、Cary Claiborne の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$13m
Jun 30 2024	n/a	n/a	-US$12m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$802k	US$466k	-US$7m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$1m	US$357k	-US$11m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$16m
Mar 31 2022	n/a	n/a	-US$17m
Dec 31 2021	US$688k	US$15k	-US$19m

報酬と市場: Caryの総報酬 ($USD 801.62K ) は、 US市場 ($USD 649.63K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Caryの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Cary Claiborne (64 yo)

2.3yrs

在職期間

US$801,621

報酬

Mr. Cary John Claiborne, MBA, is the Owner and Chief Executive Officer of Prosperity Capital Management LLC. He serves as an Independent Director at LadRx Corporation (formerly known as CytRx Corporation)...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Cary Claiborne	CEO, President & Director	2.3yrs	US$801.62k	0.95% $ 61.4k
Vinay Shah	Chief Financial Officer	no data	データなし	データなし
John Martin	Chief Legal Officer	3.8yrs	データなし	データなし
Andrew Taubman	Vice President of Corporate Development	no data	データなし	データなし
Catherine Fratila	Controller	3.8yrs	データなし	データなし

3.0yrs

平均在職期間

経験豊富な経営陣: ADILの経営陣は経験豊富であると考えられます ( 3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Cary Claiborne	CEO, President & Director	3yrs	US$801.62k	0.95% $ 61.4k
Kevin Schuyler	Chairman & Lead Independent Director	8.6yrs	US$60.22k	0.013% $ 829.4
Tony Goodman	COO & Director	7.3yrs	US$261.93k	0.0055% $ 353.3
James Newman	Independent Director	10.2yrs	US$56.22k	0.21% $ 13.7k
Robertson Gilliland	Independent Director	10.2yrs	US$53.22k	0% $ 0
J. Anderson	Independent Director	9.8yrs	US$59.22k	0% $ 0
Giovanni Addolorato	Chairperson of Scientific Advisory Board	6yrs	データなし	データなし
Tomáš Zima	Member of the Scientific Advisory Board	5.8yrs	データなし	データなし
Sebastian Mueller	Member of Scientific Advisory Board	5.8yrs	データなし	データなし

7.3yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: ADILの取締役会は経験豊富であると考えられます ( 7.3年の平均在任期間)。

Adial Pharmaceuticals マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Adial Pharmaceuticals, Inc. Announces Chief Financial Officer Changes

Adial Pharmaceuticals, Inc., Annual General Meeting, Nov 12, 2024

Adial Pharmaceuticals, Inc. Appoints Tony Goodman as Chief Operating Officer

Adial Pharmaceuticals, Inc., Annual General Meeting, Nov 02, 2023

Adial Pharmaceuticals, Inc. Announces Board Changes

Adial Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

Recent updates

Adial Pharmaceuticals, Inc. Announces Chief Financial Officer Changes

Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Genetic Diagnostic for Addiction Treatment

Adial Pharmaceuticals, Inc., Annual General Meeting, Nov 12, 2024

Adial Pharmaceuticals, Inc. Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

New major risk - Financial position

Adial Pharmaceuticals, Inc. Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend Ip Exclusivity on Core Technology to 2044

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of Ad04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals, Inc. Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $4.28365 million.

Adial Pharmaceuticals, Inc Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Adial Pharmaceuticals, Inc. announced that it has received $0.2875 million in funding

Price target decreased by 19% to US$21.00

New major risk - Share price stability

Price target decreased by 17% to US$17.00

Adial Pharmaceuticals, Inc. Appoints Tony Goodman as Chief Operating Officer

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Adial Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Adial Pharmaceuticals, Inc. announced delayed amended 10-Q filing

Adial Pharmaceuticals, Inc. announced that it has received $4.000001 million in funding

Adial Pharmaceuticals, Inc. announced that it expects to receive $4.000001 million in funding

Adial Pharmaceuticals Receives Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Adial Pharmaceuticals, Inc., Annual General Meeting, Nov 02, 2023

Adial Pharmaceuticals, Inc. Announces Board Changes

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Adial Pharmaceuticals, Inc. announced delayed 10-Q filing

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public Float

New major risk - Share price stability

Adial Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Compliance with Nasdaq Listing Rule 5550(b)(1)

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Adial Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Adial Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

Adial Pharmaceuticals, Inc. Announces Executive Changes

Adial Clinical Trial: A Fluff Or A Win?

Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01

Adial Pharmaceuticals, Inc. Announces Topline Results For Onward Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder

Adial Pharmaceuticals Announces Database Lock for the ONWARD(TM) Phase 3 Clinical Trial

Price target increased to US$10.67

Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04

Independent Director recently bought US$67k worth of stock

Adial Pharmaceuticals, Inc. announced that it has received $0.8 million in funding from Bespoke Growth Partners, Inc.

Chairman recently bought US$55k worth of stock

Adial Pharmaceuticals, Inc. Announces Positive Pre-Clinical Data for PNV2 as A Drug Candidate for Triple Negative Breast Cancer

Director William Stilley has joined 3rd company board

Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals, Inc. Reaches Full Enrollment Target for ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding from Bespoke Growth Partners, Inc., Keystone Capital Partners LLC

Adial Pharmaceuticals Provides Regulatory and Development Update

Adial Pharmaceuticals, Inc. Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic Test

Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst

Adial Pharmaceuticals, Inc. announced that it has received $2.100003 million in funding from Keystone Capital Partners LLC, Bespoke Growth Partners, Inc., Rountop Limited Partnership, LLP and another investor

Forecast breakeven pushed back to 2024

Adial Pharmaceuticals Achieves 50% Enrollment in landmark ONWARD™ Phase 3 Trial

Adial Pharmaceuticals, Inc. to File Fast Track Application for Ad04 with the FDA

New 90-day high: US$3.19

Adial Pharmaceuticals, Inc. (NasdaqCM:ADIL) completed the acquisition of Purnovate, LLC from the members of Purnovate.

New 90-day high: US$2.34

Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate

Adial Pharmaceuticals, Inc. (NasdaqCM:ADIL) entered into an Equity Purchase Agreement to acquire Purnovate, LLC from the members of Purnovate.

Adial Pharmaceuticals, Inc. Announces Management and Board Changes, Effective December 14, 2020

Adial Pharmaceuticals, Inc. announced that it expects to receive funding from Keystone Capital Partners LLC

Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital

Adial Pharmaceuticals, Inc. Announces That U.S. Food and Drug Administration Issues an Emergency Use Authorization for the Assure/Fastep® Covid-19 Igg/Igm Rapid Test Device

Adial Pharmaceuticals, Inc. Files for Expedited Review of AD04 with the FDA

Adial Pharmaceuticals, Inc. announced that it has received $0.5 million in funding from Bespoke Growth Partners, Inc.

マネジメント基準チェック /44